Hepatic Encephalopathy Market - Size, Share,
Outlook, and Opportunity Analysis, 2019-
2027
Hepatic encephalopathy (HE) is a neuropsychiatric complication commonly associated with the
liver disease: cirrhosis. The inability of the liver to metabolize ammonia results in a buildup of
ammonia, which can cross the blood–brain barrier and cause significant neurocognitive
impairment. A significant number of patients with cirrhosis may experience HE and may be at
high risk of recurrent HE.
For In depth Information Get Sample Copy of this Report @
https://www.coherentmarketinsights.com/insight/request-sample/2596
The severity of hepatic encephalopathy can be broadly categorized into two classes: Covert
Hepatic Encephalopathy (CHE) and Overt Hepatic Encephalopathy (OHE). OHE is associated
with high rates of mortality and hospitalizations and poor quality of life. Factors such as
infections, gastrointestinal bleeding, metabolic disturbance, and dietary protein overload may
cause OHE. According to a study conducted by the U.S. National Library of Medicine in 2016,
30 to 50% of patients who have cirrhosis during their clinical care are likely to develop OHE.
The global hepatic encephalopathy market was valued at US$ 2,408.3 Mn in 2017, and is
expected to witness a CAGR of 6.3% during the forecast period (2018 – 2026).
Market Dynamics
HE is a rare disease. Several drugs are available such as antibiotics, laxatives, probiotics, and
lactulose that aid in the treatment of this disease. Key players in the market are focused on
adopting acquisition strategies to expand their product portfolio. For instance, in December
2017, Mallinckrodt Pharmaceuticals announced acquisition of Ocera Therapeutics, a clinical-
stage biopharmaceutical company. Ocera Therapeutics is focused on the development and
commercialization of novel therapeutics for orphan and other severe liver diseases.
Report includes chapters which deeply display the following deliverable about industry :
• Hepatic Encephalopathy Market Research Objective and Assumption